Risk factors: Plasma renin activity predicts renal impairment

Nature Reviews Nephrology

Volumn 8, Issue 12, 2012, Pages 686-687

  Unger, Thomas ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

BIOLOGICAL MARKERS; HUMANS; HYPERTENSION, RENAL; KIDNEY DISEASES; PREDICTIVE VALUE OF TESTS; RENIN; RISK FACTORS;

EID: 84870456126     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.243     Document Type: Short Survey

References (10)

1. Sever, P. S. et al. Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehs241.
2. Tigerstedt, R. & Bergman, P. G. Niere und Kreislauf [German]. Skand. Arch. Physiol. 8, 223-271 (1898).
3. Brunner, H. R. et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N. Engl. J. Med. 286, 441-449 (1972).
4. Alderman, M. H. et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 324, 1098-1104 (1991).
5. Sealey, J. E. & Laragh, J. H. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am. J. Hypertens. 20, 587-597 (2007).
6. Masson, S. et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J. Card. Fail. 16, 964-970 (2010).
7. Tocci1, G. et al. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am. J. Hypertens. 24, 582-590 (2011).
8. White, H. D. et al. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 112, 3391-3399 (2005).
9. ONTARGET Investigators et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
10. Schefe, J. H. et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ. Res. 99, 1355-1366 (2006).